Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (8,261)	$ (4,268)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,003	1,274
Gain on sale of fixed assets	(142)	(21)
Non-cash interest	218	189
Stock-based compensation	2,138	1,056
Provision for reserve on accounts receivable	178	225
Provision for excess and obsolete inventory	388	243
Other	1	3
Changes in operating assets and liabilities, net of the effects of the acquisition:
Accounts receivable	(688)	(3,116)
Inventories	(4,130)	(1,733)
Prepaid and other assets	(469)	(330)
Accounts payable	(15)	954
Accrued liabilities	(2,064)	758
Net cash used in operating activities	(10,843)	(4,766)
Investing activities:
Purchases of property and equipment	(1,337)	(870)
Proceeds from sale of fixed assets	183	55
Acquisition of Surgalign SPV, Inc.		(17,000)
Net cash used in investing activities	(1,154)	(17,815)
Financing activities:
Payments on financing leases	(32)	(30)
Borrowings on line of credit	59,565	36,256
Repayments on line of credit	(52,288)	(34,603)
Proceeds from issuance of long term debt	5,000	5,000
Debt issuance costs	(615)	(101)
Payment of taxes from withholding of common stock on vesting of restricted stock units	(17)
Net cash provided by financing activities	11,613	6,522
Effect of exchange rate changes on cash and cash equivalents and restricted cash	(61)
Net change in cash and cash equivalents and restricted cash	(445)	(16,059)
Cash and cash equivalents and restricted cash at beginning of period	5,923	20,507
Cash and cash equivalents and restricted cash at end of period	5,478	4,448
Reconciliation of cash and cash equivalents and restricted cash reported in the condensed consolidated balance sheets
Cash and cash equivalents	5,379	4,138
Restricted cash	99	310
Total cash and restricted cash reported in condensed consolidated balance sheets	$ 5,478	$ 4,448